– ETHY-001 produced complete blockade of autoantibody-mediated TSHR activation across all patient serum samples tested, demonstrating breadth and consistency of effect –
NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- PAVS (NASDAQ:PAVS) (the "Company"), a consumer products and digital commerce solutions company, today announced that it has entered into a definitive agreement with certain institutional investors for a registered direct offering of an aggregate of 50,000,000 Class A ordinary shares (or pre-funded warrants to purchase Class A ordinary shares in lieu thereof) at a purchase price of $0.20 per share. The gross proceeds to the Company from the offering are expected to be approximately $10 million, before deducting offering expenses.
After Decades of Addiction, Baltimore Woman Reclaims Her Future as Program's 100th Graduate BALTIMORE, June 15, 2026 /PRNewswire/ -- Three years ago, Danielle Clubb...
Strategic advisory group formed to position brand for financial stability and long-term growthDALLAS, June 15, 2026 /PRNewswire/ -- Twin Peaks Restaurant today announced that...
Target-specific licensing agreement enabling Antharis to advance proprietary dual-payload antibody-drug conjugate (ADC) programs using Lonza's site-specific ADC technologiesReinforces Antharis' and Lonza's position at the forefront...
BAYPORT, Minn., June 15, 2026 /PRNewswire/ -- The Andersen Corporate Foundation has committed over $1.2 million to 86 nonprofit organizations in its spring 2026...
DELRAY BEACH, Fla., June 15, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Stem Cell Therapy Market is projected to grow from about USD 0.48 billion...
The Project includes a 14-year open-pit silver project delivering strong economics, a rapid 1.9 year payback, and a 63.7-million-ounce payable silver production profile with significant...
SUZHOU, China, June 15, 2026 /PRNewswire/ -- This month, Suzhou Anta Scaffolding Engineering Co., Ltd. (Anta Scaffolding), a Chinese scaffolding manufacturer and supplier, announced that...